Evalve

Evalve

Cardiologist Frederick St. Goar and medical device executive Ferolyn Powell launched Evalve in 1999 with technology licensed from Stanford University. The company focused on percutaneous mitral valve repair, a procedure that threads a tiny clip through a vein to the heart, eliminating the need for open-heart surgery. The startup operated out of Menlo Park, California, and drew early support from venture investors including Three Arch Partners and New Enterprise Associates. Evalve developed the MitraClip device, the first transcatheter therapy for degenerative mitral regurgitation. The system received CE Mark approval in Europe during 2008, establishing a commercial foothold in Germany, Italy, and the UK before U.S. clearance. The company's clinical strategy rested on the landmark EVEREST trial, which enrolled patients at dozens of North American sites and demonstrated safety and efficacy for the novel catheter-based approach. MitraClip targeted a large, underserved population of heart-failure patients too frail for conventional surgery. Before its exit, Evalve employed fewer than 200 professionals and maintained a lean operating footprint. Abbott Laboratories acquired the company in 2009, paying $320 million upfront plus milestone-based consideration that brought the total to as much as $410 million (per FierceMedicalDevices, 2009). Abbott integrated MitraClip into its structural heart division, where the franchise has since generated billions in cumulative revenue. Evalve's founders and backers realized returns through the acquisition, though remaining equity positions were held by the acquirer. Evalve's structural differentiator was the simplicity of its edge-to-edge repair concept, which copied a surgical stitch technique pioneered by Italian cardiac surgeon Ottavio Alfieri and miniaturized it for transcatheter delivery. The design translated an open-surgery manual stitch into an implantable clip mechanism — a form-factor reduction that allowed interventional cardiologists, rather than cardiac surgeons, to treat the valve. This procedural shift expanded the treatable patient pool and reshaped mitral regurgitation care pathways across multiple continents.